Harvard Pilgrim Health Care | TUFTS Health Plan

Point32Health companies

Payment Policy:

Laboratory: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Effective date: Nov. 1, 2025

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products
☐ Tufts Health Plan Commercial products

Public Plans Products

☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan
☐ Tufts Health One Care – A dual-eligible product

Senior Products

☐ Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
☐ Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

To manage loss of response due to the development of anti-drug antibodies, immunopharmacologic monitoring of circulating drug and anti-drug antibody levels has been proposed. The presence of anti-drug antibodies may promote adverse effects and diminish drug efficacy (Tighe & McNamara, 2017).

Targeted inhibitors of tumor necrosis factor-alpha (TNF) are widely used in the treatment of several inflammatory conditions, including rheumatoid arthritis (RA), spondyloarthritis, inflammatory bowel disease, and psoriasis. Some of these targeted inhibitors include, but are not limited to, infliximab, adalimumab, etanercept, and golimumab.

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

1. For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti-tumor necrosis factor (anti-TNF) therapies, vedolizumab therapy, or ustekinumab therapy **MEETS COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

2. For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti-TNF therapies **DOES NOT MEET COVERAGE CRITERIA**.
3. For all other situations not addressed above, measurement of the serum drug levels and/or measurement of the antibodies to the drugs **DOES NOT MEET COVERAGE CRITERIA** for any of the following drugs (alone or as a combination test):
   a. adalimumab
   b. certolizumab
   c. etanercept
   d. golimumab
   e. infliximab
   f. infliximab-dyyb
   g. infliximab-abda
   h. rituximab
   i. ustekinumab
   j. vedolizumab

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
80145	Adalimumab
80230	Infliximab
80280	Vedolizumab
80299	Quantitation of therapeutic drug, not elsewhere specified
82397	Chemiluminescent assay
84999	Unlisted chemistry procedure

Evidence-based Scientific References

1. Kirkham B. Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases. Updated March 17, 2025. https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-induction-of-antibodies-autoantibodies-and-autoimmune-diseases
2. Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World journal of gastroenterology. Jan 21 2017;23(3):414-425. doi:10.3748/wjg.v23.i3.414
4. Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci. 2014:1175-85. vol. 6.
5. Wallace ZS, Sparks JA. Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. JAMA. 2021;326(23):2370-2372. doi:10.1001/jama.2021.21315
6. Lichtenstein G. Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors. Updated December 04, 2023. https://www.uptodate.com/contents/treatment-of-crohn-disease-in-adults-dosing-and-monitoring-of-tumor-necrosis-factor-alpha-inhibitors
7. UpToDate®. Ustekinumab (including biosimilars): Drug information. https://www.uptodate.com/contents/ustekinumab-including-biosimilars-drug-information
8. UpToDate®. Vedolizumab: Drug information. https://www.uptodate.com/contents/vedolizumab-drug-information
9. Theradiag. Miraca Life Sciences, Theradiag's partner in the USA, becomes Inform Diagnostics. Updated January 19, 2018. https://www.theradiag.com/wp-content/uploads/2017/12/PR_Theradiag_19012018_InformDX.pdf
10. Prometheus Laboratories. Therapeutic Drug Monitoring. https://prometheuslabs.com/anser/about-the-tests/
11. LabCorp. Certolizumab and Anti-Certolizumab Antibody, DoseASSURE™ CTZ. https://www.labcorp.com/tests/504627/certolizumab-and-anti-certolizumab-antibody-i-dose-i-assure-ctz
12. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. Journal of immunological methods. Aug 31 2012;382(1-2):177-88. doi:10.1016/j.jim.2012.06.002
13. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. Journal of pharmaceutical and biomedical analysis. May 5 2013;78-79:39-44. doi:10.1016/j.jpba.2013.01.031
14. Van Stappen T, Bollen L, Vande Casteele N, et al. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clinical and translational gastroenterology. Dec 08 2016;7(12):e206. doi:10.1038/ctg.2016.62
15. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. Jun 2014;63(6):919-27. doi:10.1136/gutjnl-2013-305279
16. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. The American journal of gastroenterology. Aug 2014;109(8):1250-6. doi:10.1038/ajg.2014.146. Epub 2014 Jun 10.
17. Mitchell RA, Shuster C, Shahidi N, et al. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Canadian journal of gastroenterology & hepatology. 2016;2016:5203898. doi:10.1155/2016/5203898
18. Barlow NL, Mohammed P, Berg JD. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring. Annals of clinical biochemistry. Jul 2016;53(Pt 4):477-84. doi:10.1177/0004563215604866

19. Moore C, Corbett G, Moss AC. Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. Journal of Crohn's & colitis. May 2016;10(5):619-25. doi:10.1093/ecco-jcc/jjw007
20. Fernandes SR, Bernardo S, Simoes C, et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflammatory bowel diseases. Jun 27 2019;doi:10.1093/ibd/izz131
21. Negoescu DM, Enns EA, Swanhorst B, et al. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflammatory bowel diseases. Jun 10 2019;doi:10.1093/ibd/izz113
22. Papamichael K, Juncadella A, Wong D, et al. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. Journal of Crohn's & colitis. Aug 14 2019;13(8):976-981. doi:10.1093/ecco-jcc/jjz018
23. Guido AJ, Crandall W, Homan E, et al. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. Jan 2020;70(1):48-54. doi:10.1097/MPG.0000000000002486
24. Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021;326(23):2375-2384. doi:10.1001/jama.2021.21316
25. Cox M, Smith R, Wild G, Dunkley L. P001 What is the role of antidrug antibody and drug level testing in patients treated with infliximab and adalimumab? Rheumatology. 2021;60(Supplement_1):keab247. doi:10.1093/rheumatology/keab247
26. Pan Y, Ahmed W, Mahtani P, et al. Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease. Inflammatory bowel diseases. Dec 1 2022;28(12):1865-1871. doi:10.1093/ibd/izac030
27. NICE. Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | Guidance and guidelines | NICE. NICE. https://www.nice.org.uk/guidance/dg22/chapter/1-Recommendations
28. NICE. Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) | Guidance and guidelines | NICE. NICE. https://www.nice.org.uk/guidance/dg36/chapter/1-Recommendations
29. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. Sep 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032
30. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017;153(3):835-857.e6. doi:10.1053/j.gastro.2017.07.031
31. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research. 2019/01/01 2019;71(1):2-29. doi:10.1002/acr.23789
32. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. 2018;113(4):481-517. doi:10.1038/ajg.2018.27
33. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Official journal of the American College of Gastroenterology | ACG. 2025;120(6):1225-1264. doi:10.14309/ajg.0000000000003465
34. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. The American journal of gastroenterology. Mar 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152
35. Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. Aug 2019;17(9):1655-1668.e3. doi:10.1016/j.cgh.2019.03.037
36. Cheifetz AS, Abreu M, Afif W, et al. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021;doi:10.14309/ajg.0000000000001396

Publication History

03/01/2026: Annual review; administrative edits
09/01/2025: Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider’s network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment,

nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable), adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.